Detalhe da pesquisa
1.
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Nature
; 578(7794): 306-310, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31969702
2.
Identification of VEGF Signaling Inhibition-Induced Glomerular Injury in Rats through Site-Specific Urinary Biomarkers.
Int J Mol Sci
; 22(23)2021 Nov 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34884436
3.
Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors.
Bioorg Med Chem Lett
; 28(10): 1804-1810, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29678460
4.
Methylpyrrole inhibitors of BET bromodomains.
Bioorg Med Chem Lett
; 27(10): 2225-2233, 2017 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28268136
5.
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
Invest New Drugs
; 33(4): 870-80, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25933833
6.
Monitoring tumor response to linifanib therapy with SPECT/CT using the integrin αvß3-targeted radiotracer 99mTc-3P-RGD2.
J Pharmacol Exp Ther
; 346(2): 251-8, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23750021
7.
Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
J Pharmacol Exp Ther
; 343(3): 617-27, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22935731
8.
Exploration of diverse hinge-binding scaffolds for selective Aurora kinase inhibitors.
Bioorg Med Chem Lett
; 22(14): 4528-31, 2012 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22727637
9.
Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases.
Bioorg Med Chem Lett
; 22(14): 4750-5, 2012 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22695126
10.
Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.
Bioorg Med Chem Lett
; 22(9): 3208-12, 2012 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22465635
11.
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.
In Vivo
; 36(4): 1615-1627, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35738590
12.
ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models.
J Pharmacol Exp Ther
; 338(1): 134-42, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21505059
13.
Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.
Blood
; 113(17): 4052-62, 2009 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-19144991
14.
Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
Bioorg Med Chem Lett
; 21(18): 5620-4, 2011 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21778056
15.
Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors.
ACS Med Chem Lett
; 12(7): 1108-1115, 2021 Jul 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34267880
16.
Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia.
Mol Cancer Ther
; 20(10): 1809-1819, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34253595
17.
Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain.
J Med Chem
; 63(10): 5585-5623, 2020 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32324999
18.
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.
Leukemia
; 34(6): 1646-1657, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31827241
19.
Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition.
J Pharmacol Exp Ther
; 329(3): 928-37, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19255283
20.
ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats.
J Cardiovasc Pharmacol
; 53(2): 173-8, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19188829